The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K.
Kim DW, et al. Among authors: al hallak mn.
Future Oncol. 2024 Feb 13. doi: 10.2217/fon-2023-0824. Online ahead of print.
Future Oncol. 2024.
PMID: 38348690
Free article.
Review.